Integrated Care Systems go live in the NHS - reflections after 3 weeks
Pharma Market Access Insights - from Petauri EvidenceShow Notes
Send us Fan Mail On 1st July we saw the introduction of legislation for Integrated Care Systems (ICSs) in the NHS. In the weeks since, what has changed for healthcare leaders, practitioners and patients? What are the key priorities for NHS decision-makers and what is getting in the way of change? How can Pharma and Medtech support their NHS customers as they implement this change? In this episode Tom Clarke (Director, Mtech Access) explored all this and more with Steve Reed (Head of C...
More from Pharma Market Access Insights - from Petauri Evidence
Send us Fan Mail How will Most Favored Nation (MFN) pricing reshape global pharmaceutical strategy? What do emerging Centers for Medicare & Medicaid Service (CMS) models such as GENEROUS, GLOBE, and GUARD mean for launch planning, pricing corridors, and payer expectations worldwide? How should global market access teams prepare for a more transparent and tightly connected pricing environment? MFN reform is already influencing how companies plan, price, and launch medicines around the worl...
Send us Fan Mail How do LATAM healthcare markets differ and what do these differences mean for Pharma and Medtech launch planning? What should global market access teams know to support affiliates in Argentina, Brazil, Colombia, and Mexico? How do evidence requirements, access routes, and payer expectations vary across the region? For global market access teams planning for launch in Latin America (LATAM), understanding the diversity and complexity of this region is essential. Healthcare sys...
Send us Fan Mail What does the evolving NHS landscape look like through the eyes of a Chief Pharmacist, and how are integrated care system (ICS) pharmacy teams responding? In this Petauri Evidence NHS Whispers session, we put your questions to Yousaf Ahmad (Chief Pharmacist and Director of Medicines Optimisation, Frimley ICS), as he shares how he and his colleagues are responding to the changing NHS environment. From system pressures and financial constraints to prescribing priorities and ser...
Send us Fan Mail What makes Switzerland a compelling first-launch market for Pharma? How does its healthcare system compare to other European countries? What do manufacturers need to know about reimbursement, pricing, and evidence requirements? How might the evolving Joint Clinical Assessment (JCA) landscape influence launch sequencing? This episode explores Switzerland’s potential as an early launch market. In this session, Louise Maddison (Senior Consultant – Global Pricing and Market Acc...
Send us Fan Mail In this NHS Whispers live Q&A webinar, Katie Mulholland (Senior Consultant, UK Market Access, Petauri Evidence) speaks to: - Sarah Everest Ford (Programme Director, Health and Care Partnership) - Patrick McGee (Deputy Programme Director for Pathology, Lancashire & South Cumbria) - Prof. Phil Richardson (Former Dorset ICS System Commissioning Director; now Chief Innovation Officer, Petauri Evidence) Together, they explore the implications of changing...